CSIMarket
 


Roivant Sciences Ltd   (ROIV)
Other Ticker:  
 

Roivant Sciences Ltd 's Quick Ratio

ROIV's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Roivant Sciences Ltd 's Cash & cash equivalent grew by 373.7 % in the III Quarter 2023 sequentially, while Current Liabilities decreased, this led to improvement in Roivant Sciences Ltd 's Quick Ratio to 27.24 a new company high.

Within Major Pharmaceutical Preparations industry Roivant Sciences Ltd booked the highest Quick Ratio than Roivant Sciences Ltd in the third quarter 2023. While Quick Ratio total ranking has improved so far during the III Quarter 2023 to 5, from total ranking in the second quarter 2023 at 554.

Explain Quick Ratio?
How much Cash & cash equivalents ROIV´s has?
What are ROIV´s Current Liabilities?


ROIV Quick Ratio (Dec 31 2023)
III. Quarter
(Sep 30 2023)
II. Quarter
(Jun 30 2023)
I. Quarter
(Mar 31 2023)
IV. Quarter
(Dec 31 2022)
III. Quarter
Y / Y Current Liabilities Change 0.26 % 15.08 % -25.51 % 47.77 % 51.98 %
Y / Y Cash & cash equivalent Change 336.73 % -11.93 % -26.16 % -18.62 % -31.02 %
Quick Ratio MRQ 27.24 5.3 5.85 6.15 6.25
ROIV's Total Ranking # 5 # 554 # 506 # 482 # 39
Seq. Current Liabilities Change -7.78 % 8.38 % -10.07 % 11.54 % 5.86 %
Seq. Cash & cash equivalent Change 373.7 % -1.8 % -14.48 % 9.78 % -4.48 %



Quick Ratio third quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 1
Healthcare Sector # 1
Overall Market # 5


Quick Ratio Statistics
High Average Low
27.24 9.68 5.3
(Dec 31 2023)   (Sep 30 2023)




Financial Statements
Roivant Sciences Ltd 's Current Liabilities $ 245 Millions Visit ROIV's Balance sheet
Roivant Sciences Ltd 's Cash & cash equivalent $ 6,671 Millions Visit ROIV's Balance sheet
Source of ROIV's Sales Visit ROIV's Sales by Geography


Cumulative Roivant Sciences Ltd 's Quick Ratio

ROIV's Quick Ratio for the trailling 12 Months

ROIV Quick Ratio

(Dec 31 2023)
III. Quarter
(Sep 30 2023)
II. Quarter
(Jun 30 2023)
I. Quarter
(Mar 31 2023)
IV. Quarter
(Dec 31 2022)
III. Quarter
Y / Y Current Liabilities TTM Growth 0.26 % 15.08 % -25.51 % 47.77 % 51.98 %
Y / Y Cash & cash equivalent TTM Growth 336.73 % -11.93 % -26.16 % -18.62 % -31.02 %
Quick Ratio TTM 10.89 5.89 6.28 6.27 7.21
Total Ranking TTM # 394 # 420 # 2881 # 3631 # 524
Seq. Current Liabilities TTM Growth -7.78 % 8.38 % -10.07 % 11.54 % 5.86 %
Seq. Cash & cash equivalent TTM Growth 373.7 % -1.8 % -14.48 % 9.78 % -4.48 %


On the trailing twelve months basis ROIV Cash & cash equivalent more than doubled by 336.73 % in III Quarter 2023 year on year, faster than Current Liabilities, this led to increase in in Roivant Sciences Ltd 's Quick Ratio to 10.89, above ROIV average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 20 other companies have achieved higher Quick Ratio than Roivant Sciences Ltd . While Quick Ratio overall ranking has improved so far to 394, from total ranking during the twelve months ending second quarter 2023 at 420.

Explain Quick Ratio?
How much Cash & cash equivalents ROIV´s has?
What are ROIV´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 21
Healthcare Sector # 52
Within the Market # 394


trailing twelve months Quick Ratio Statistics
High Average Low
10.89 7.78 5.89
(Dec 31 2023)   (Sep 30 2023)




Companies with similar Quick Ratio in the quarter ending Dec 31 2023, within Major Pharmaceutical Preparations Industry Quick RatioDec 31 2023 MRQ Cash & cash equivalentDec 31 2023 MRQ Current Liabilities
Moonlake Immunotherapeutics  51.28 $ 511.008  Millions$ 9.966  Millions
Essa Pharma inc   40.25 $ 142.120  Millions$ 3.531  Millions
Verona Pharma Plc  36.18 $ 271.772  Millions$ 7.512  Millions
Xbiotech Inc   32.79 $ 200.023  Millions$ 6.100  Millions
Vistagen Therapeutics Inc   30.39 $ 126.559  Millions$ 4.165  Millions
Morphic Holding inc   28.43 $ 704.349  Millions$ 24.776  Millions
Roivant Sciences Ltd   27.24 $ 6,670.810  Millions$ 244.899  Millions
Belite Bio Inc  24.27 $ 88.157  Millions$ 3.633  Millions
Astria Therapeutics inc   21.97 $ 246.530  Millions$ 11.221  Millions
Diamedica Therapeutics Inc   19.57 $ 52.895  Millions$ 2.703  Millions
Edgewise Therapeutics inc   18.98 $ 318.393  Millions$ 16.771  Millions
Structure Therapeutics Inc   18.89 $ 467.323  Millions$ 24.740  Millions
Sagimet Biosciences inc   16.98 $ 94.897  Millions$ 5.589  Millions
Protagonist Therapeutics inc   16.06 $ 341.617  Millions$ 21.274  Millions
Lyell Immunopharma Inc   15.82 $ 546.223  Millions$ 34.519  Millions
Agios Pharmaceuticals Inc   14.67 $ 776.928  Millions$ 52.947  Millions
Anixa Biosciences Inc   14.34 $ 23.798  Millions$ 1.660  Millions
Keros Therapeutics Inc   13.59 $ 331.147  Millions$ 24.373  Millions
Vyne Therapeutics Inc   12.38 $ 93.307  Millions$ 7.538  Millions
Rallybio Corporation  11.87 $ 109.929  Millions$ 9.263  Millions
Gh Research Plc  11.70 $ 78.420  Millions$ 6.701  Millions
Rezolute Inc   11.56 $ 92.598  Millions$ 8.008  Millions
Immuneering Corporation  11.35 $ 85.666  Millions$ 7.545  Millions
Compass Pathways Plc  11.25 $ 220.640  Millions$ 19.604  Millions
Anaptysbio Inc   10.96 $ 390.904  Millions$ 35.665  Millions
Prothena Corporation Public Limited Company  10.88 $ 618.830  Millions$ 56.891  Millions
Cassava Sciences Inc  10.86 $ 121.136  Millions$ 11.158  Millions
Cymabay Therapeutics Inc   10.70 $ 394.255  Millions$ 36.843  Millions
Spyre Therapeutics Inc   10.61 $ 339.277  Millions$ 31.978  Millions
Ovid Therapeutics Inc   10.35 $ 105.833  Millions$ 10.228  Millions

Date modified: 2024-02-13T17:32:25+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com